episesamin profile

Episesamin is a lignan found in sesame seeds. It is a potent inhibitor of the enzyme, cytochrome P450 1A1 (CYP1A1), which is involved in the metabolism of a variety of carcinogens and other foreign compounds. Episesamin has been shown to protect against cancer in animal studies, and it is currently being investigated as a potential cancer chemopreventive agent in humans. Episesamin is also a potent antioxidant, and it has been shown to protect cells from damage caused by oxidative stress. Additionally, Episesamin has been shown to have anti-inflammatory properties. Episesamin is being studied for its potential benefits in a variety of diseases, including cancer, heart disease, and Alzheimer's disease.'

1-asarinine: structure; might this actually be asarinin?(sb) [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

ID Source	ID
PubMed CID	101612
CHEMBL ID	43469
SCHEMBL ID	976772
MeSH ID	M0153022

Synonym
nsc 31773
1,3-benzodioxole, 5,5'-(tetrahydro-1h,3h-furo(3,4-c)furan-1,4-diyl)bis-, (1alpha,3a alpha,4beta,6a alpha)-
unii-f6pwy73zgt
ai3-00810
1-asarinine
133-05-1
f6pwy73zgt ,
SPECTRUM5_000490
asarinin
nsc-31773
DIVK1C_007054
SDCCGMLS-0066831.P001
SPECTRUM4_001725
SPECTRUM_001556
NCGC00017230-01
tnp00112
ACON1_000986
BSPBIO_002743
MEGXP0_001224
episesamin
KBIOSS_002036
KBIOGR_002110
KBIO1_001998
KBIO2_007172
KBIO2_004604
KBIO2_002036
KBIO3_002243
SPBIO_000701
SPECTRUM2_000811
SPECTRUM3_001162
SPECPLUS_000958
SPECTRUM1504180
NCGC00169785-02
NCGC00169785-01
CHEMBL43469
l-asarinin
smr001397394
MLS002473313
bdbm50101976
5-[(3r,3ar,6s,6ar)-3-(1,3-benzodioxol-5-yl)-1,3,3a,4,6,6a-hexahydrofuro[3,4-c]furan-6-yl]-1,3-benzodioxole
asarinin, (+)-
1,3-benzodioxole, 5,5'-(tetrahydro-1h,3h-furo(3,4-c)furan-1,4-diyl)bis-, (+)-
ai3-21202
ai 3-21202
unii-c3rvx72nmg
133-03-9
c3rvx72nmg ,
HMS2223C09
CCG-39667
5-[(3s,3ar,6r,6ar)-3-(1,3-benzodioxol-5-yl)-1,3,3a,4,6,6a-hexahydrofuro[3,4-c]furan-6-yl]-1,3-benzodioxole
(-)-episesamin
1,3-benzodioxole, 5,5'-(tetrahydro-1h,3h-furo(3,4-c)furan-1,4-diyl)bis-, (1s-(1.alpha.,3a.alpha.,4.beta.,6a.alpha.))-
1h,3h-furo(3,4-c)furan, 3a.beta.,4,6,6a.beta.-tetrahydro-1.alpha.,4.beta.-bis(3,4-(methylenedioxy)phenyl)-, (+)-
(+)-episesamin
d-asarinin
(+)-asarinin
asarinin d-form [mi]
isosesamin
1,3-benzodioxole, 5,5'-((1r,3ar,4s,6ar)-tetrahydro-1h,3h-furo(3,4-c)furan-1,4-diyl)bis-, rel-
asarinin, (+/-)-
asarinin dl-form [mi]
1,3-benzodioxole, 5,5'-(tetrahydro-1h,3h-furo(3,4-c)furan-1,4-diyl)bis-, (1.alpha.,3a.alpha.,4.beta.,6a.alpha.)-
SCHEMBL976772
asarinin (-)
(-)-asarinin, >=98% (hplc)
ncgc00169785-04!5-[(3r,3ar,6s,6ar)-3-(1,3-benzodioxol-5-yl)-1,3,3a,4,6,6a-hexahydrofuro[3,4-c]furan-6-yl]-1,3-benzodioxole
l-asarinin/(-)-asarinin
(1r,3ar,4s,6ar)-1,4-di(benzo[d][1,3]dioxol-5-yl)hexahydrofuro[3,4-c]furan
1,3-benzodioxole, 5,5'-[(1r,3ar,4s,6ar)-tetrahydro-1h,3h-furo[3,4-c]furan-1,4-diyl]bis-, rel-
5,5'-(tetrahydro-1h,3h-furo[3,4-c]furan-1,4-diyl)bis(1,3-benzodioxole)
D85162
(-)-asarinin 97
AS-76837
DTXSID201033462
AKOS040750231

Protein	Taxonomy	Measurement	Average (µ)	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
glp-1 receptor, partial	Homo sapiens (human)	Potency	12.5893	0.0184	6.8060	14.1254	AID624417
TDP1 protein	Homo sapiens (human)	Potency	23.1093	0.0008	11.3822	44.6684	AID686978
cytochrome P450 2D6 isoform 1	Homo sapiens (human)	Potency	15.8489	0.0020	7.5337	39.8107	AID891
cytochrome P450 2C19 precursor	Homo sapiens (human)	Potency	3.1623	0.0025	5.8400	31.6228	AID899
cytochrome P450 2C9 precursor	Homo sapiens (human)	Potency	3.9811	0.0063	6.9043	39.8107	AID883
chromobox protein homolog 1	Homo sapiens (human)	Potency	79.4328	0.0060	26.1688	89.1251	AID540317
nuclear factor erythroid 2-related factor 2 isoform 2	Homo sapiens (human)	Potency	23.1093	0.0041	9.9848	25.9290	AID504444
parathyroid hormone/parathyroid hormone-related peptide receptor precursor	Homo sapiens (human)	Potency	50.1187	3.5481	19.5427	44.6684	AID743266
Histamine H2 receptor	Cavia porcellus (domestic guinea pig)	Potency	3.9811	0.0063	8.2350	39.8107	AID883
TAR DNA-binding protein 43	Homo sapiens (human)	Potency	11.2202	1.7783	16.2081	35.4813	AID652104
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Cytochrome P450 2C9	Homo sapiens (human)	Ki	6.8000	0.0003	1.6842	10.0000	AID1209210
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Cytochrome P450 1A2	Homo sapiens (human)	Km	11.9000	5.0000	7.0000	9.0000	AID1209204
Cytochrome P450 2C9	Homo sapiens (human)	Km	15.8000	0.1900	2.4300	5.4000	AID1209200
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Process	via Protein(s)	Taxonomy
steroid catabolic process	Cytochrome P450 1A2	Homo sapiens (human)
porphyrin-containing compound metabolic process	Cytochrome P450 1A2	Homo sapiens (human)
xenobiotic metabolic process	Cytochrome P450 1A2	Homo sapiens (human)
cholesterol metabolic process	Cytochrome P450 1A2	Homo sapiens (human)
estrogen metabolic process	Cytochrome P450 1A2	Homo sapiens (human)
toxin biosynthetic process	Cytochrome P450 1A2	Homo sapiens (human)
post-embryonic development	Cytochrome P450 1A2	Homo sapiens (human)
alkaloid metabolic process	Cytochrome P450 1A2	Homo sapiens (human)
regulation of gene expression	Cytochrome P450 1A2	Homo sapiens (human)
monoterpenoid metabolic process	Cytochrome P450 1A2	Homo sapiens (human)
dibenzo-p-dioxin metabolic process	Cytochrome P450 1A2	Homo sapiens (human)
epoxygenase P450 pathway	Cytochrome P450 1A2	Homo sapiens (human)
lung development	Cytochrome P450 1A2	Homo sapiens (human)
methylation	Cytochrome P450 1A2	Homo sapiens (human)
monocarboxylic acid metabolic process	Cytochrome P450 1A2	Homo sapiens (human)
xenobiotic catabolic process	Cytochrome P450 1A2	Homo sapiens (human)
retinol metabolic process	Cytochrome P450 1A2	Homo sapiens (human)
long-chain fatty acid biosynthetic process	Cytochrome P450 1A2	Homo sapiens (human)
cellular respiration	Cytochrome P450 1A2	Homo sapiens (human)
aflatoxin metabolic process	Cytochrome P450 1A2	Homo sapiens (human)
hydrogen peroxide biosynthetic process	Cytochrome P450 1A2	Homo sapiens (human)
oxidative demethylation	Cytochrome P450 1A2	Homo sapiens (human)
cellular response to cadmium ion	Cytochrome P450 1A2	Homo sapiens (human)
omega-hydroxylase P450 pathway	Cytochrome P450 1A2	Homo sapiens (human)
xenobiotic metabolic process	Cytochrome P450 2C9	Homo sapiens (human)
steroid metabolic process	Cytochrome P450 2C9	Homo sapiens (human)
cholesterol metabolic process	Cytochrome P450 2C9	Homo sapiens (human)
estrogen metabolic process	Cytochrome P450 2C9	Homo sapiens (human)
monoterpenoid metabolic process	Cytochrome P450 2C9	Homo sapiens (human)
epoxygenase P450 pathway	Cytochrome P450 2C9	Homo sapiens (human)
urea metabolic process	Cytochrome P450 2C9	Homo sapiens (human)
monocarboxylic acid metabolic process	Cytochrome P450 2C9	Homo sapiens (human)
xenobiotic catabolic process	Cytochrome P450 2C9	Homo sapiens (human)
long-chain fatty acid biosynthetic process	Cytochrome P450 2C9	Homo sapiens (human)
amide metabolic process	Cytochrome P450 2C9	Homo sapiens (human)
icosanoid biosynthetic process	Cytochrome P450 2C9	Homo sapiens (human)
oxidative demethylation	Cytochrome P450 2C9	Homo sapiens (human)
omega-hydroxylase P450 pathway	Cytochrome P450 2C9	Homo sapiens (human)
negative regulation of protein phosphorylation	TAR DNA-binding protein 43	Homo sapiens (human)
mRNA processing	TAR DNA-binding protein 43	Homo sapiens (human)
RNA splicing	TAR DNA-binding protein 43	Homo sapiens (human)
negative regulation of gene expression	TAR DNA-binding protein 43	Homo sapiens (human)
regulation of protein stability	TAR DNA-binding protein 43	Homo sapiens (human)
positive regulation of insulin secretion	TAR DNA-binding protein 43	Homo sapiens (human)
response to endoplasmic reticulum stress	TAR DNA-binding protein 43	Homo sapiens (human)
positive regulation of protein import into nucleus	TAR DNA-binding protein 43	Homo sapiens (human)
regulation of circadian rhythm	TAR DNA-binding protein 43	Homo sapiens (human)
regulation of apoptotic process	TAR DNA-binding protein 43	Homo sapiens (human)
negative regulation by host of viral transcription	TAR DNA-binding protein 43	Homo sapiens (human)
rhythmic process	TAR DNA-binding protein 43	Homo sapiens (human)
regulation of cell cycle	TAR DNA-binding protein 43	Homo sapiens (human)
3'-UTR-mediated mRNA destabilization	TAR DNA-binding protein 43	Homo sapiens (human)
3'-UTR-mediated mRNA stabilization	TAR DNA-binding protein 43	Homo sapiens (human)
nuclear inner membrane organization	TAR DNA-binding protein 43	Homo sapiens (human)
amyloid fibril formation	TAR DNA-binding protein 43	Homo sapiens (human)
regulation of gene expression	TAR DNA-binding protein 43	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
monooxygenase activity	Cytochrome P450 1A2	Homo sapiens (human)
iron ion binding	Cytochrome P450 1A2	Homo sapiens (human)
protein binding	Cytochrome P450 1A2	Homo sapiens (human)
electron transfer activity	Cytochrome P450 1A2	Homo sapiens (human)
oxidoreductase activity	Cytochrome P450 1A2	Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen	Cytochrome P450 1A2	Homo sapiens (human)
enzyme binding	Cytochrome P450 1A2	Homo sapiens (human)
heme binding	Cytochrome P450 1A2	Homo sapiens (human)
demethylase activity	Cytochrome P450 1A2	Homo sapiens (human)
caffeine oxidase activity	Cytochrome P450 1A2	Homo sapiens (human)
aromatase activity	Cytochrome P450 1A2	Homo sapiens (human)
estrogen 16-alpha-hydroxylase activity	Cytochrome P450 1A2	Homo sapiens (human)
estrogen 2-hydroxylase activity	Cytochrome P450 1A2	Homo sapiens (human)
hydroperoxy icosatetraenoate dehydratase activity	Cytochrome P450 1A2	Homo sapiens (human)
monooxygenase activity	Cytochrome P450 2C9	Homo sapiens (human)
iron ion binding	Cytochrome P450 2C9	Homo sapiens (human)
arachidonic acid epoxygenase activity	Cytochrome P450 2C9	Homo sapiens (human)
steroid hydroxylase activity	Cytochrome P450 2C9	Homo sapiens (human)
arachidonic acid 14,15-epoxygenase activity	Cytochrome P450 2C9	Homo sapiens (human)
arachidonic acid 11,12-epoxygenase activity	Cytochrome P450 2C9	Homo sapiens (human)
oxidoreductase activity	Cytochrome P450 2C9	Homo sapiens (human)
(S)-limonene 6-monooxygenase activity	Cytochrome P450 2C9	Homo sapiens (human)
(S)-limonene 7-monooxygenase activity	Cytochrome P450 2C9	Homo sapiens (human)
caffeine oxidase activity	Cytochrome P450 2C9	Homo sapiens (human)
(R)-limonene 6-monooxygenase activity	Cytochrome P450 2C9	Homo sapiens (human)
aromatase activity	Cytochrome P450 2C9	Homo sapiens (human)
heme binding	Cytochrome P450 2C9	Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen	Cytochrome P450 2C9	Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA binding	TAR DNA-binding protein 43	Homo sapiens (human)
DNA binding	TAR DNA-binding protein 43	Homo sapiens (human)
double-stranded DNA binding	TAR DNA-binding protein 43	Homo sapiens (human)
RNA binding	TAR DNA-binding protein 43	Homo sapiens (human)
mRNA 3'-UTR binding	TAR DNA-binding protein 43	Homo sapiens (human)
protein binding	TAR DNA-binding protein 43	Homo sapiens (human)
lipid binding	TAR DNA-binding protein 43	Homo sapiens (human)
identical protein binding	TAR DNA-binding protein 43	Homo sapiens (human)
pre-mRNA intronic binding	TAR DNA-binding protein 43	Homo sapiens (human)
molecular condensate scaffold activity	TAR DNA-binding protein 43	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
endoplasmic reticulum membrane	Cytochrome P450 1A2	Homo sapiens (human)
intracellular membrane-bounded organelle	Cytochrome P450 1A2	Homo sapiens (human)
intracellular membrane-bounded organelle	Cytochrome P450 1A2	Homo sapiens (human)
endoplasmic reticulum membrane	Cytochrome P450 2C9	Homo sapiens (human)
plasma membrane	Cytochrome P450 2C9	Homo sapiens (human)
intracellular membrane-bounded organelle	Cytochrome P450 2C9	Homo sapiens (human)
cytoplasm	Cytochrome P450 2C9	Homo sapiens (human)
intracellular membrane-bounded organelle	Cytochrome P450 2C9	Homo sapiens (human)
intracellular non-membrane-bounded organelle	TAR DNA-binding protein 43	Homo sapiens (human)
nucleus	TAR DNA-binding protein 43	Homo sapiens (human)
nucleoplasm	TAR DNA-binding protein 43	Homo sapiens (human)
perichromatin fibrils	TAR DNA-binding protein 43	Homo sapiens (human)
mitochondrion	TAR DNA-binding protein 43	Homo sapiens (human)
cytoplasmic stress granule	TAR DNA-binding protein 43	Homo sapiens (human)
nuclear speck	TAR DNA-binding protein 43	Homo sapiens (human)
interchromatin granule	TAR DNA-binding protein 43	Homo sapiens (human)
nucleoplasm	TAR DNA-binding protein 43	Homo sapiens (human)
chromatin	TAR DNA-binding protein 43	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (60)

Assay ID	Title	Year	Journal	Article
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845	Primary qHTS for Inhibitors of ATXN expression
AID504810	Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	2010	Endocrinology, Jul, Volume: 151, Issue:7	A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635	Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID504812	Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	2010	Endocrinology, Jul, Volume: 151, Issue:7	A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1209230	Activity of recombinant human CYP1A2 expressed in Saccharomyces cerevisiae AH22 cells assessed as enzyme-mediated episesamin dicatechol formation at 2 to 75 uM after 15 mins by HPLC analysis in presence of NADPH	2012	Drug metabolism and disposition: the biological fate of chemicals, Oct, Volume: 40, Issue:10	Comparison of metabolism of sesamin and episesamin by drug-metabolizing enzymes in human liver.
AID1209228	Activity of recombinant human CYP2C19 expressed in Saccharomyces cerevisiae AH22 cells assessed as enzyme-mediated (S)-episesamin monocatechol formation at 2 to 75 uM after 15 mins by HPLC analysis in presence of NADPH	2012	Drug metabolism and disposition: the biological fate of chemicals, Oct, Volume: 40, Issue:10	Comparison of metabolism of sesamin and episesamin by drug-metabolizing enzymes in human liver.
AID655419	Inhibition of NFkappaB-mediated COX2 mRNA expression in human TNFalpha-stimulated human HepG2 cells by RT-PCR analysis	2012	Bioorganic & medicinal chemistry letters, Apr-01, Volume: 22, Issue:7	Anti-inflammatory and PPAR transactivational effects of secondary metabolites from the roots of Asarum sieboldii.
AID1209219	Drug metabolism in human liver microsomes assessed as episesamin dicatechol formation at 2 to 75 uM after 15 mins by HPLC analysis in presence of NADPH	2012	Drug metabolism and disposition: the biological fate of chemicals, Oct, Volume: 40, Issue:10	Comparison of metabolism of sesamin and episesamin by drug-metabolizing enzymes in human liver.
AID1209209	Mechanism-based inhibition of recombinant human CYP3A4 expressed in microsomes isolated from Saccharomyces cerevisiae AH22 cells up to 50 uM preincubated for 5 to 10 mins followed by substrate addition measured after 15 mins by HPLC analysis	2012	Drug metabolism and disposition: the biological fate of chemicals, Oct, Volume: 40, Issue:10	Comparison of metabolism of sesamin and episesamin by drug-metabolizing enzymes in human liver.
AID1209205	Activity of recombinant human CYP1A2 expressed in Saccharomyces cerevisiae AH22 cells assessed as Kcat/Km for enzyme-mediated episesamin monocatecholization after 15 mins by Michaelis-Menten plot analysis in presence of NADPH	2012	Drug metabolism and disposition: the biological fate of chemicals, Oct, Volume: 40, Issue:10	Comparison of metabolism of sesamin and episesamin by drug-metabolizing enzymes in human liver.
AID1209226	Activity of recombinant human CYP2C9 expressed in Saccharomyces cerevisiae AH22 cells assessed as enzyme-mediated (R)-episesamin monocatechol formation at 2 to 75 uM after 15 mins by HPLC analysis in presence of NADPH	2012	Drug metabolism and disposition: the biological fate of chemicals, Oct, Volume: 40, Issue:10	Comparison of metabolism of sesamin and episesamin by drug-metabolizing enzymes in human liver.
AID1209191	Drug metabolism in human liver microsomes assessed as (R)-episesamin monocatechol formation at 2 to 75 uM after 15 mins by HPLC analysis in presence of NADPH	2012	Drug metabolism and disposition: the biological fate of chemicals, Oct, Volume: 40, Issue:10	Comparison of metabolism of sesamin and episesamin by drug-metabolizing enzymes in human liver.
AID1209224	Activity of recombinant human CYP2C9 expressed in Saccharomyces cerevisiae AH22 cells assessed as enzyme-mediated (S)-episesamin monocatechol formation at 2 to 75 uM after 15 mins by HPLC analysis in presence of NADPH	2012	Drug metabolism and disposition: the biological fate of chemicals, Oct, Volume: 40, Issue:10	Comparison of metabolism of sesamin and episesamin by drug-metabolizing enzymes in human liver.
AID1209195	Drug metabolism in human liver microsomes assessed as (S)-episesamin monocatechol formation at 5 uM after 15 mins by HPLC analysis in presence of NADPH and anti-CYP1A2 antibody	2012	Drug metabolism and disposition: the biological fate of chemicals, Oct, Volume: 40, Issue:10	Comparison of metabolism of sesamin and episesamin by drug-metabolizing enzymes in human liver.
AID1209192	Drug metabolism in heat-inactivated human liver microsomes assessed as episesamin dicatechol formation at 2 to 75 uM after 15 mins by HPLC analysis in presence of NADPH	2012	Drug metabolism and disposition: the biological fate of chemicals, Oct, Volume: 40, Issue:10	Comparison of metabolism of sesamin and episesamin by drug-metabolizing enzymes in human liver.
AID1209198	Drug metabolism in human liver microsomes assessed as episesamin monocatecholization at 5 uM after 15 mins by HPLC analysis in presence of NADPH and CYP2C9 inhibitor sulfaphenazole	2012	Drug metabolism and disposition: the biological fate of chemicals, Oct, Volume: 40, Issue:10	Comparison of metabolism of sesamin and episesamin by drug-metabolizing enzymes in human liver.
AID1209220	Activity of recombinant human CYP2D6 expressed in Saccharomyces cerevisiae AH22 cells assessed as enzyme-mediated catecholization at 2 to 75 uM after 15 mins by HPLC analysis in presence of NADPH	2012	Drug metabolism and disposition: the biological fate of chemicals, Oct, Volume: 40, Issue:10	Comparison of metabolism of sesamin and episesamin by drug-metabolizing enzymes in human liver.
AID1209173	Drug metabolism in Sprague-Dawley rat liver microsomes assessed as CYP450-mediated catecholization after 10 to 30 mins by HPLC analysis in presence of NADPH	2012	Drug metabolism and disposition: the biological fate of chemicals, Oct, Volume: 40, Issue:10	Comparison of metabolism of sesamin and episesamin by drug-metabolizing enzymes in human liver.
AID1209234	Ratio of Kinact to Ki(app) for mechanism-based inhibition of recombinant human CYP2C9 expressed in microsomes isolated from Saccharomyces cerevisiae AH22 cells assessed as diclofenac 4'-hydroxylation preincubated for 5 to 10 mins followed by substrate add	2012	Drug metabolism and disposition: the biological fate of chemicals, Oct, Volume: 40, Issue:10	Comparison of metabolism of sesamin and episesamin by drug-metabolizing enzymes in human liver.
AID1209199	Drug metabolism in human liver microsomes assessed as episesamin monocatecholization at 5 uM after 15 mins by HPLC analysis in presence of NADPH and CYP2C19 inhibitor (+)-N-3-benzylnirvanol	2012	Drug metabolism and disposition: the biological fate of chemicals, Oct, Volume: 40, Issue:10	Comparison of metabolism of sesamin and episesamin by drug-metabolizing enzymes in human liver.
AID1209174	Drug metabolism in Sprague-Dawley rat liver microsomes assessed as CYP450-mediated catecholization per mg of protein after 10 to 30 mins by HPLC analysis in presence of NADPH	2012	Drug metabolism and disposition: the biological fate of chemicals, Oct, Volume: 40, Issue:10	Comparison of metabolism of sesamin and episesamin by drug-metabolizing enzymes in human liver.
AID1209221	Activity of recombinant human CYP2E1 expressed in Saccharomyces cerevisiae AH22 cells assessed as enzyme-mediated catecholization at 2 to 75 uM after 15 mins by HPLC analysis in presence of NADPH	2012	Drug metabolism and disposition: the biological fate of chemicals, Oct, Volume: 40, Issue:10	Comparison of metabolism of sesamin and episesamin by drug-metabolizing enzymes in human liver.
AID1209222	Activity of recombinant human CYP1A2 expressed in Saccharomyces cerevisiae AH22 cells assessed as enzyme-mediated (R)-episesamin monocatechol formation at 2 to 75 uM after 15 mins by HPLC analysis in presence of NADPH	2012	Drug metabolism and disposition: the biological fate of chemicals, Oct, Volume: 40, Issue:10	Comparison of metabolism of sesamin and episesamin by drug-metabolizing enzymes in human liver.
AID1209204	Activity of recombinant human CYP1A2 expressed in Saccharomyces cerevisiae AH22 cells assessed as enzyme-mediated episesamin monocatecholization after 15 mins by Michaelis-Menten plot analysis in presence of NADPH	2012	Drug metabolism and disposition: the biological fate of chemicals, Oct, Volume: 40, Issue:10	Comparison of metabolism of sesamin and episesamin by drug-metabolizing enzymes in human liver.
AID1209208	Mechanism-based inhibition of recombinant human CYP1A2 expressed in microsomes isolated from Saccharomyces cerevisiae AH22 cells up to 50 uM preincubated for 5 to 10 mins followed by substrate addition measured after 15 mins by HPLC analysis	2012	Drug metabolism and disposition: the biological fate of chemicals, Oct, Volume: 40, Issue:10	Comparison of metabolism of sesamin and episesamin by drug-metabolizing enzymes in human liver.
AID1209212	Drug metabolism in human liver microsomes assessed as CYP450-mediated catecholization after 10 to 30 mins by HPLC analysis in presence of NADPH	2012	Drug metabolism and disposition: the biological fate of chemicals, Oct, Volume: 40, Issue:10	Comparison of metabolism of sesamin and episesamin by drug-metabolizing enzymes in human liver.
AID1209197	Drug metabolism in human liver microsomes assessed as (R)-episesamin monocatechol formation at 5 uM after 15 mins by HPLC analysis in presence of NADPH and anti-CYP2C9 antibody	2012	Drug metabolism and disposition: the biological fate of chemicals, Oct, Volume: 40, Issue:10	Comparison of metabolism of sesamin and episesamin by drug-metabolizing enzymes in human liver.
AID977602	Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM	2013	Molecular pharmacology, Jun, Volume: 83, Issue:6	Structure-based identification of OATP1B1/3 inhibitors.
AID1209232	Activity of recombinant human CYP2C19 expressed in Saccharomyces cerevisiae AH22 cells assessed as enzyme-mediated episesamin dicatechol formation at 2 to 75 uM after 15 mins by HPLC analysis in presence of NADPH	2012	Drug metabolism and disposition: the biological fate of chemicals, Oct, Volume: 40, Issue:10	Comparison of metabolism of sesamin and episesamin by drug-metabolizing enzymes in human liver.
AID655418	Inhibition of NFkappaB-mediated iNOS mRNA expression in human TNFalpha-stimulated human HepG2 cells pretreated for 1 hr before TNFalpha challenge measured after 6 hrs by RT-PCR analysis	2012	Bioorganic & medicinal chemistry letters, Apr-01, Volume: 22, Issue:7	Anti-inflammatory and PPAR transactivational effects of secondary metabolites from the roots of Asarum sieboldii.
AID586667	Induction of NRF2/ARE enhancer activity rat PC12 cells transfected with ARE-firefly luciferase reporter gene at 10 uM after 24 hrs by luciferase assay	2011	Bioorganic & medicinal chemistry, Mar-15, Volume: 19, Issue:6	Involvement of heme oxygenase-1 induction via Nrf2/ARE activation in protection against H2O2-induced PC12 cell death by a metabolite of sesamin contained in sesame seeds.
AID1209210	Mechanism-based inhibition of recombinant human CYP2C9 expressed in microsomes isolated from Saccharomyces cerevisiae AH22 cells assessed as diclofenac 4'-hydroxylation preincubated for 5 to 10 mins followed by substrate addition measured after 15 mins by	2012	Drug metabolism and disposition: the biological fate of chemicals, Oct, Volume: 40, Issue:10	Comparison of metabolism of sesamin and episesamin by drug-metabolizing enzymes in human liver.
AID977599	Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM	2013	Molecular pharmacology, Jun, Volume: 83, Issue:6	Structure-based identification of OATP1B1/3 inhibitors.
AID1209201	Activity of recombinant human CYP2C9 expressed in Saccharomyces cerevisiae AH22 cells assessed as Kcat/Km for enzyme-mediated episesamin monocatecholization after 15 mins by Michaelis-Menten plot analysis in presence of NADPH	2012	Drug metabolism and disposition: the biological fate of chemicals, Oct, Volume: 40, Issue:10	Comparison of metabolism of sesamin and episesamin by drug-metabolizing enzymes in human liver.
AID275100	Cytotoxicity against murine 3T3 cells by MTT assay	2007	Journal of natural products, Jan, Volume: 70, Issue:1	An efficient and stereoselective dearylation of asarinin and sesamin tetrahydrofurofuran lignans to acuminatolide by methyltrioxorhenium/H(2)O(2) and UHP systems.
AID655417	Inhibition of TNFalpha-induced NFkappaB transcriptional activity in human HepG2 cells pretreated for 1 hr before TNFalpha challenge by luciferase reporter gene analysis	2012	Bioorganic & medicinal chemistry letters, Apr-01, Volume: 22, Issue:7	Anti-inflammatory and PPAR transactivational effects of secondary metabolites from the roots of Asarum sieboldii.
AID1209231	Activity of recombinant human CYP2C9 expressed in Saccharomyces cerevisiae AH22 cells assessed as enzyme-mediated episesamin dicatechol formation at 2 to 75 uM after 15 mins by HPLC analysis in presence of NADPH	2012	Drug metabolism and disposition: the biological fate of chemicals, Oct, Volume: 40, Issue:10	Comparison of metabolism of sesamin and episesamin by drug-metabolizing enzymes in human liver.
AID1209196	Drug metabolism in human liver microsomes assessed as (R)-episesamin monocatechol formation at 5 uM after 15 mins by HPLC analysis in presence of NADPH and anti-CYP1A2 antibody	2012	Drug metabolism and disposition: the biological fate of chemicals, Oct, Volume: 40, Issue:10	Comparison of metabolism of sesamin and episesamin by drug-metabolizing enzymes in human liver.
AID1209190	Drug metabolism in human liver microsomes assessed as (S)-episesamin monocatechol formation at 2 to 75 uM after 15 mins by HPLC analysis in presence of NADPH	2012	Drug metabolism and disposition: the biological fate of chemicals, Oct, Volume: 40, Issue:10	Comparison of metabolism of sesamin and episesamin by drug-metabolizing enzymes in human liver.
AID1209194	Drug metabolism in human liver microsomes assessed as (S)-episesamin monocatechol formation at 5 uM after 15 mins by HPLC analysis in presence of NADPH and anti-CYP2C9 antibody	2012	Drug metabolism and disposition: the biological fate of chemicals, Oct, Volume: 40, Issue:10	Comparison of metabolism of sesamin and episesamin by drug-metabolizing enzymes in human liver.
AID1209171	Drug metabolism in human liver microsomes assessed as CYP450-mediated catecholization per mg of protein after 10 to 30 mins by HPLC analysis in presence of NADPH	2012	Drug metabolism and disposition: the biological fate of chemicals, Oct, Volume: 40, Issue:10	Comparison of metabolism of sesamin and episesamin by drug-metabolizing enzymes in human liver.
AID1209200	Activity of recombinant human CYP2C9 expressed in Saccharomyces cerevisiae AH22 cells assessed as enzyme-mediated episesamin monocatecholization after 15 mins by Michaelis-Menten plot analysis in presence of NADPH	2012	Drug metabolism and disposition: the biological fate of chemicals, Oct, Volume: 40, Issue:10	Comparison of metabolism of sesamin and episesamin by drug-metabolizing enzymes in human liver.
AID655420	Transactivation of PPAR expressed in HepG2 cells after 20 hrs by luminescence assay	2012	Bioorganic & medicinal chemistry letters, Apr-01, Volume: 22, Issue:7	Anti-inflammatory and PPAR transactivational effects of secondary metabolites from the roots of Asarum sieboldii.
AID652615	Cytotoxicity against human HepG2 cells by MTT assay	2012	Bioorganic & medicinal chemistry letters, Apr-01, Volume: 22, Issue:7	Anti-inflammatory and PPAR transactivational effects of secondary metabolites from the roots of Asarum sieboldii.
AID1209217	Drug metabolism in human liver microsomes assessed as (R)-episesamin monocatechol formation at 5 uM after 30 mins by HPLC analysis in presence of NADPH	2012	Drug metabolism and disposition: the biological fate of chemicals, Oct, Volume: 40, Issue:10	Comparison of metabolism of sesamin and episesamin by drug-metabolizing enzymes in human liver.
AID1209227	Activity of recombinant human CYP2C19 expressed in Saccharomyces cerevisiae AH22 cells assessed as enzyme-mediated (R)-episesamin monocatechol formation at 2 to 75 uM after 15 mins by HPLC analysis in presence of NADPH	2012	Drug metabolism and disposition: the biological fate of chemicals, Oct, Volume: 40, Issue:10	Comparison of metabolism of sesamin and episesamin by drug-metabolizing enzymes in human liver.
AID1209211	Mechanism-based inhibition of recombinant human CYP2C9 expressed in microsomes isolated from Saccharomyces cerevisiae AH22 cells assessed as diclofenac 4'-hydroxylation up to 50 uM preincubated for 5 to 10 mins followed by substrate addition measured by H	2012	Drug metabolism and disposition: the biological fate of chemicals, Oct, Volume: 40, Issue:10	Comparison of metabolism of sesamin and episesamin by drug-metabolizing enzymes in human liver.
AID1209235	Activity of recombinant human CYP3A4 expressed in Saccharomyces cerevisiae AH22 cells assessed as enzyme-mediated catecholization at 2 to 75 uM after 15 mins by HPLC analysis in presence of NADPH	2012	Drug metabolism and disposition: the biological fate of chemicals, Oct, Volume: 40, Issue:10	Comparison of metabolism of sesamin and episesamin by drug-metabolizing enzymes in human liver.
AID1503774	Cytotoxicity against human HL cells assessed as cell viability at 50 uM after 72 hrs by resazurin dye based fluorescence assay relative to control	2017	Journal of natural products, 10-27, Volume: 80, Issue:10	Identification of Privileged Antichlamydial Natural Products by a Ligand-Based Strategy.
AID1209216	Drug metabolism in human liver microsomes assessed as (S)-episesamin monocatechol formation at 5 uM after 30 mins by HPLC analysis in presence of NADPH	2012	Drug metabolism and disposition: the biological fate of chemicals, Oct, Volume: 40, Issue:10	Comparison of metabolism of sesamin and episesamin by drug-metabolizing enzymes in human liver.
AID1159607	Screen for inhibitors of RMI FANCM (MM2) intereaction	2016	Journal of biomolecular screening, Jul, Volume: 21, Issue:6	A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	2 (16.67)	29.6817
2010's	9 (75.00)	24.3611
2020's	1 (8.33)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	0 (0.00%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	12 (100.00%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Classes	Roles
ciprofibrate [no description available]	2.07	1	cyclopropanes; monocarboxylic acid; organochlorine compound	antilipemic drug
gossypol Gossypol: A dimeric sesquiterpene found in cottonseed (GOSSYPIUM). The (-) isomer is active as a male contraceptive (CONTRACEPTIVE AGENTS, MALE) whereas toxic symptoms are associated with the (+) isomer.	2.15	1
nalidixic acid [no description available]	2.15	1	1,8-naphthyridine derivative; monocarboxylic acid; quinolone antibiotic	antibacterial drug; antimicrobial agent; DNA synthesis inhibitor
ofloxacin Ofloxacin: A synthetic fluoroquinolone antibacterial agent that inhibits the supercoiling activity of bacterial DNA GYRASE, halting DNA REPLICATION.. 9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid : An oxazinoquinoline that is 2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinolin-7-one substituted by methyl, carboxy, fluoro, and 4-methylpiperazin-1-yl groups at positions 3, 6, 9, and 10, respectively.. ofloxacin : A racemate comprising equimolar amounts of levofloxacin and dextrofloxacin. It is a synthetic fluoroquinolone antibacterial agent which inhibits the supercoiling activity of bacterial DNA gyrase, halting DNA replication.	2.15	1	3-oxo monocarboxylic acid; N-arylpiperazine; N-methylpiperazine; organofluorine compound; oxazinoquinoline
pd 98059 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one: inhibits MAP kinase kinase (MEK) activity, p42 MAPK and p44 MAPK; structure in first source. 2-(2-amino-3-methoxyphenyl)chromen-4-one : A member of the class of monomethoxyflavones that is 3'-methoxyflavone bearing an additional amino substituent at position 2'.	2.06	1	aromatic amine; monomethoxyflavone	EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor; geroprotector
sulfasalazine Sulfasalazine: A drug that is used in the management of inflammatory bowel diseases. Its activity is generally considered to lie in its metabolic breakdown product, 5-aminosalicylic acid (see MESALAMINE) released in the colon. (From Martindale, The Extra Pharmacopoeia, 30th ed, p907). sulfasalazine : An azobenzene consisting of diphenyldiazene having a carboxy substituent at the 4-position, a hydroxy substituent at the 3-position and a 2-pyridylaminosulphonyl substituent at the 4'-position.	2.07	1
troglitazone Troglitazone: A chroman and thiazolidinedione derivative that acts as a PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS (PPAR) agonist. It was formerly used in the treatment of TYPE 2 DIABETES MELLITUS, but has been withdrawn due to hepatotoxicity.	2.07	1	chromanes; thiazolidinone	anticoagulant; anticonvulsant; antineoplastic agent; antioxidant; EC 6.2.1.3 (long-chain-fatty-acid--CoA ligase) inhibitor; ferroptosis inhibitor; hypoglycemic agent; platelet aggregation inhibitor; vasodilator agent
cycloheximide Cycloheximide: Antibiotic substance isolated from streptomycin-producing strains of Streptomyces griseus. It acts by inhibiting elongation during protein synthesis.. cycloheximide : A dicarboximide that is 4-(2-hydroxyethyl)piperidine-2,6-dione in which one of the hydrogens attached to the carbon bearing the hydroxy group is replaced by a 3,5-dimethyl-2-oxocyclohexyl group. It is an antibiotic produced by the bacterium Streptomyces griseus.	2.15	1	antibiotic fungicide; cyclic ketone; dicarboximide; piperidine antibiotic; piperidones; secondary alcohol	anticoronaviral agent; bacterial metabolite; ferroptosis inhibitor; neuroprotective agent; protein synthesis inhibitor
methyleugenol methyleugenol: structure	2.07	1	phenylpropanoid
pyrazolanthrone pyrazolanthrone: JNK (c-Jun N-terminal kinase) inhibitor; structure in first source. anthra[1,9-cd]pyrazol-6(2H)-one : A member of the class of anthrapyrazoles that is anthra[1,9-cd]pyrazole substituted at position 6 by an oxo group. An inhibitor of c-Jun N-terminal kinase.	2.06	1	anthrapyrazole; aromatic ketone; cyclic ketone	antineoplastic agent; c-Jun N-terminal kinase inhibitor; geroprotector
jervine jervine: teratogen from Veratrum grandiflorum; RN given refers to parent cpd(3beta,23beta)-isomer; structure	2.15	1	piperidines
indirubin [no description available]	2.15	1
osthol osthol: from Cnidium monnieri and Angelica pubescens (both Apiaceae); structure given in first source	2.15	1	botanical anti-fungal agent; coumarins	metabolite
oleanolic acid [no description available]	2.15	1	hydroxy monocarboxylic acid; pentacyclic triterpenoid	plant metabolite
hesperidin Hesperidin: A flavanone glycoside found in CITRUS fruit peels.. hesperidin : A disaccharide derivative that consists of hesperetin substituted by a 6-O-(alpha-L-rhamnopyranosyl)-beta-D-glucopyranosyl moiety at position 7 via a glycosidic linkage.	2.15	1	3'-hydroxyflavanones; 4'-methoxyflavanones; dihydroxyflavanone; disaccharide derivative; flavanone glycoside; monomethoxyflavanone; rutinoside	mutagen
bezafibrate [no description available]	2.07	1	aromatic ether; monocarboxylic acid amide; monocarboxylic acid; monochlorobenzenes	antilipemic drug; environmental contaminant; geroprotector; xenobiotic
baccatin iii [no description available]	2.15	1	acetate ester; benzoate ester; tetracyclic diterpenoid	plant metabolite
epicatechin (-)-epicatechin : A catechin with (2R,3R)-configuration.	2.15	1	catechin; polyphenol	antioxidant
honokiol [no description available]	2.15	1	biphenyls
sesamin (+)-sesamin : A lignan that consists of tetrahydro-1H,3H-furo[3,4-c]furan substituted by 1,3-benzodioxole groups at positions 1 and 4 (the 1S,3aR,4S,6aR stereoisomer). Isolated from Cinnamomum camphora, it exhibits cytotoxic activity.	7.76	3	benzodioxoles; furofuran; lignan	antineoplastic agent; neuroprotective agent; plant metabolite
eriocitrin eriocitrin: structure in first source. eriocitrin : A disaccharide derivative that consists of eriodictyol substituted by a 6-O-(alpha-L-rhamnopyranosyl)-beta-D-glucopyranosyl moiety at position 7 via a glycosidic linkage.	2.15	1	3'-hydroxyflavanones; 4'-hydroxyflavanones; disaccharide derivative; flavanone glycoside; rutinoside; trihydroxyflavanone	antioxidant
lupinine lupinine: RN given refers to parent cpd(1R-trans)-isomer; structure	2.15	1	quinolizidine alkaloid
podocarpic acid podocarpic acid: structure. podocarpic acid : An abietane diterpenoid lacking the isopropyl substituent with an aromatic C-ring and a hydroxy group at the 12-position.	2.15	1	abietane diterpenoid
tryptoline tryptoline: neurotoxic factor that may be involved in development of Parkinson's disease; enzymatic prep from human brain converts tryptamine to tryptoline; RN given refers to parent cpd; structure	2.15	1	beta-carbolines
deguelin deguelin: a natural product from Mundulea sericea; RN refers to (7aS-cis)-isomer; structure given in first source. deguelin : A rotenone that is 13,13a-dihydro-3H-chromeno[3,4-b]pyrano[2,3-h]chromen-7(7aH)-one substituted by methoxy groups at positions 9 and 10, and by two methyl groups at position 3 (the 7aS,13aS-stereoisomer). It exists in abundant quantities in the bark, roots, and leaves of the Leguminosae family of plants and reported to exert anti-tumour effects in various cancers.	2.15	1	aromatic ether; diether; organic heteropentacyclic compound; rotenones	angiogenesis inhibitor; anti-inflammatory agent; antineoplastic agent; antiviral agent; apoptosis inducer; EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor; mitochondrial NADH:ubiquinone reductase inhibitor; plant metabolite
leucodin leucodin: structure in first source	2.15	1	sesquiterpene lactone
sb 203580 [no description available]	2.06	1	imidazoles; monofluorobenzenes; pyridines; sulfoxide	EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor; EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor; geroprotector; Hsp90 inhibitor; neuroprotective agent
graveoline graveoline: structure in first source	2.15	1	quinolines
taxifolin (+)-taxifolin : A taxifolin that has (2R,3R)-configuration.	2.15	1	taxifolin	metabolite
digitoxin Digitoxin: A cardiac glycoside sometimes used in place of DIGOXIN. It has a longer half-life than digoxin; toxic effects, which are similar to those of digoxin, are longer lasting. (From Martindale, The Extra Pharmacopoeia, 30th ed, p665). digitoxin : A cardenolide glycoside in which the 3beta-hydroxy group of digitoxigenin carries a 2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1->4)-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1->4)-2,6-dideoxy-beta-D-ribo-hexopyranosyl trisaccharide chain.	2.15	1	cardenolide glycoside	EC 3.6.3.9 (Na(+)/K(+)-transporting ATPase) inhibitor
dihydroergocristine monomesylate dihydroergocristine mesylate : The methanesulfonic acid salt of dihydroergocristine. It has been used as the for the symptomatic treatment of mental deterioration associated with cerebrovascular insufficiency and in peripheral vascular disease. It is also a component of ergoloid mesylate (codergocrine mesilate), a mixture of ergot alkaloid derivatives that is used as a vasodilator and has shown mild benefits in the treatment of vascular dementia.	2.15	1	methanesulfonate salt	alpha-adrenergic antagonist; geroprotector; vasodilator agent
mycophenolic acid Mycophenolic Acid: Compound derived from Penicillium stoloniferum and related species. It blocks de novo biosynthesis of purine nucleotides by inhibition of the enzyme inosine monophosphate dehydrogenase (IMP DEHYDROGENASE). Mycophenolic acid exerts selective effects on the immune system in which it prevents the proliferation of T-CELLS, LYMPHOCYTES, and the formation of antibodies from B-CELLS. It may also inhibit recruitment of LEUKOCYTES to sites of INFLAMMATION.. mycophenolate : A monocarboxylic acid anion resulting from the removal of a proton from the carboxy group of mycophenolic acid.. mycophenolic acid : A member of the class of 2-benzofurans that is 2-benzofuran-1(3H)-one which is substituted at positions 4, 5, 6, and 7 by methyl, methoxy, (2E)-5-carboxy-3-methylpent-2-en-1-yl, and hydroxy groups, respectively. It is an antibiotic produced by Penicillium brevi-compactum, P. stoloniferum, P. echinulatum and related species. An immunosuppressant, it is widely used (partiularly as its sodium salt and as the 2-(morpholin-4-yl)ethyl ester prodrug, mycophenolate mofetil) to prevent tissue rejection following organ transplants and for the treatment of certain autoimmune diseases.	2.15	1	2-benzofurans; gamma-lactone; monocarboxylic acid; phenols	anticoronaviral agent; antimicrobial agent; antineoplastic agent; EC 1.1.1.205 (IMP dehydrogenase) inhibitor; environmental contaminant; immunosuppressive agent; mycotoxin; Penicillium metabolite; xenobiotic
aphidicolin Aphidicolin: An antiviral antibiotic produced by Cephalosporium aphidicola and other fungi. It inhibits the growth of eukaryotic cells and certain animal viruses by selectively inhibiting the cellular replication of DNA polymerase II or the viral-induced DNA polymerases. The drug may be useful for controlling excessive cell proliferation in patients with cancer, psoriasis or other dermatitis with little or no adverse effect upon non-multiplying cells.. aphidicolin : A tetracyclic diterpenoid that has an tetradecahydro-8,11a-methanocyclohepta[a]naphthalene skeleton with two hydroxymethyl substituents at positions 4 and 9, two methyl substituents at positions 4 and 11b and two hydroxy substituents at positions 3 and 9. An antibiotic with antiviral and antimitotical properties. Aphidicolin is a reversible inhibitor of eukaryotic nuclear DNA replication.	2.15	1	tetracyclic diterpenoid	antimicrobial agent; antimitotic; antineoplastic agent; antiviral drug; apoptosis inducer; Aspergillus metabolite; DNA synthesis inhibitor; EC 2.7.7.7 (DNA-directed DNA polymerase) inhibitor; fungal metabolite
epipinoresinol epipinoresinol : An enantiomer of pinoresinol having (+)-(1R,3aR,4S,6aR)-configuration.	2.07	1	pinoresinol	marine metabolite; plant metabolite
vasicine vasicine: RN given refers to (R)-isomer	2.15	1
caryophyllene oxide caryophyllene oxide: has butyrylcholinesterase inhibitory activity; structure in first source. epoxide : Any cyclic ether in which the oxygen atom forms part of a 3-membered ring.	2.15	1	epoxide	metabolite
u 0126 U 0126: protein kinase kinase inhibitor; structure in first source	2.06	1	aryl sulfide; dinitrile; enamine; substituted aniline	antineoplastic agent; antioxidant; apoptosis inducer; EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor; osteogenesis regulator; vasoconstrictor agent
manool manool: structure in first source. manool : A labdane diterpenoid in which the labdane skeleton has double bonds at positions 8(17) and 14 and carries an R-hydroxy group at position 13.	2.15	1	labdane diterpenoid; tertiary alcohol	antibacterial agent; antineoplastic agent; plant metabolite
5,6-dehydrokawain 5,6-dehydrokawain: from Alpinia speciosa rhizoma; RN given for cpd without isomeric designation; structure given in first source	2.15	1	2-pyranones; aromatic ether
prostaglandin b1 prostaglandin Bx: phospholipase A2 inhibitor; polymeric derivative of diketo-PGB1; mean MW 2,200. prostaglandin B1 : A member of the class of prostaglandins B that is prosta-8(12),13-dien-1-oic acid carrying oxo and hydroxy substituents at positions 9 and 15 respectively (the 13E,15S-stereoisomer).	2.15	1	prostaglandins B	human metabolite
apigetrin apigetrin: structure given in first source. apigenin 7-O-beta-D-glucoside : A glycosyloxyflavone that is apigenin substituted by a beta-D-glucopyranosyl moiety at position 7 via a glycosidic linkage.	2.15	1	beta-D-glucoside; dihydroxyflavone; glycosyloxyflavone; monosaccharide derivative	antibacterial agent; metabolite; non-steroidal anti-inflammatory drug
quercetin 3-o-glucopyranoside quercetin 3-O-glucopyranoside: structure in first source. quercetin 3-O-beta-D-glucopyranoside : A quercetin O-glucoside that is quercetin with a beta-D-glucosyl residue attached at position 3. Isolated from Lepisorus contortus, it exhibits antineoplastic activityand has been found to decrease the rate of polymerization and sickling of red blood cells	2.15	1	beta-D-glucoside; monosaccharide derivative; quercetin O-glucoside; tetrahydroxyflavone	antineoplastic agent; antioxidant; antipruritic drug; bone density conservation agent; geroprotector; histamine antagonist; osteogenesis regulator; plant metabolite
chartreusin chartreusin: structure	2.15	1	benzochromenone; glycoside
chrysin chrysin : A dihydroxyflavone in which the two hydroxy groups are located at positions 5 and 7.	2.15	1	7-hydroxyflavonol; dihydroxyflavone	anti-inflammatory agent; antineoplastic agent; antioxidant; EC 2.7.11.18 (myosin-light-chain kinase) inhibitor; hepatoprotective agent; plant metabolite
coumestrol Coumestrol: A daidzein derivative occurring naturally in forage crops which has some estrogenic activity.. coumestrol : A member of the class of coumestans that is coumestan with hydroxy substituents at positions 3 and 9.	2.15	1	coumestans; delta-lactone; polyphenol	anti-inflammatory agent; antioxidant; plant metabolite
caffeic acid phenethyl ester phenethyl caffeate : An alkyl caffeate ester in which 2-phenylethyl is the alkyl component.	2.15	1	alkyl caffeate ester	anti-inflammatory agent; antibacterial agent; antineoplastic agent; antioxidant; antiviral agent; immunomodulator; metabolite; neuroprotective agent
7-hydroxyflavone 7-hydroxyflavone : A hydroxyflavonoid in which the flavone nucleus is substituted at position 7 by a hydroxy group.	2.15	1	hydroxyflavonoid
natamycin [no description available]	2.15	1	antibiotic antifungal drug; dicarboxylic acid monoester; epoxide; macrolide antibiotic; monosaccharide derivative; polyene antibiotic	antifungal agrochemical; antimicrobial food preservative; apoptosis inducer; bacterial metabolite; ophthalmology drug
veratrine Veratrine: A voltage-gated sodium channel activator.	2.15	1	alkaloid
monorden monorden: inhibits HSP90 Heat-Shock Proteins, DNA topoisomerase VI and human Topoisomerase II	2.15	1	cyclic ketone; enone; epoxide; macrolide antibiotic; monochlorobenzenes; phenols	antifungal agent; metabolite; tyrosine kinase inhibitor
l-165041 4-(3-(2-propyl-3-hydroxy-4-acetyl)phenoxy)propyloxyphenoxy acetic acid: a PPAR-delta agonist has regulatory effects on a variety of adipokines, and these effects might explain some of their metabolic function.	2.07	1	aromatic ketone
cinobufagin cinobufagin: isolated from Chinese medicinal preparation ch'an su; derived from toad venom	2.15	1	steroid lactone

Condition	Relationship Strength	Studies
Innate Inflammatory Response [description not available]	2.47	2
Inflammation A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.	2.47	2
Anemia, Fanconi [description not available]	2.13	1
Fanconi Anemia Congenital disorder affecting all bone marrow elements, resulting in ANEMIA; LEUKOPENIA; and THROMBOPENIA, and associated with cardiac, renal, and limb malformations as well as dermal pigmentary changes. Spontaneous CHROMOSOME BREAKAGE is a feature of this disease along with predisposition to LEUKEMIA. There are at least 7 complementation groups in Fanconi anemia: FANCA, FANCB, FANCC, FANCD1, FANCD2, FANCE, FANCF, FANCG, and FANCL. (from Online Mendelian Inheritance in Man, http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=227650, August 20, 2004)	2.13	1

episesamin

Description

Cross-References

Synonyms (75)

Research Excerpts

Protein Targets (12)

Potency Measurements

Inhibition Measurements

Other Measurements

Biological Processes (45)

Molecular Functions (30)

Ceullar Components (13)

Bioassays (60)

Research

Studies (12)

Market Indicators

Research Demand Index: 19.62

Study Types

episesamin

Description

Cross-References

Synonyms (75)

Research Excerpts

Protein Targets (12)

Potency Measurements

Inhibition Measurements

Other Measurements

Biological Processes (45)

Molecular Functions (30)

Ceullar Components (13)

Bioassays (60)

Research

Studies (12)

Market Indicators

Research Demand Index: 19.62

Study Types

Related Drugs (52)

Related Conditions (4)